How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 17 01 2018
revised: 26 09 2018
accepted: 27 09 2018
pubmed: 28 11 2018
medline: 31 3 2020
entrez: 28 11 2018
Statut: ppublish

Résumé

How might time to healthy singleton delivery affect decision-making during infertility treatment? This was a Delphi consensus investigating expert opinion that comprised three steps. In Step 1, 12 experts developed statements. In Step 2, 27 experts (including 12 from Step 1) voted (online survey) on their agreement/disagreement with each statement (providing reasons). Consensus was reached if ≥66% of participants agreed/disagreed. Statements not reaching consensus were revised and the process repeated until consensus was achieved. In Step 3 details of the final agreed statements were communicated. Twelve statements were developed, and consensus (agreement) was reached on all after one round of voting. Time to healthy singleton delivery should be taken into consideration when making decisions related to infertility treatment, and it is important that fertility treatment is provided in a timely manner, avoiding over- or under-treatment. In all subfertile women <40 years old, IVF outcomes could be optimized by performing up to six single-embryo transfers and certain procedures might reduce time to healthy singleton delivery. These procedures include preimplantation genetic testing for aneuploidies, frozen replacement cycles immediately after failed fresh cycles and use of gonadotrophin-releasing hormone antagonists. Finally, the number of oocytes retrieved should be maximized to increase cumulative live birth rate.

Identifiants

pubmed: 30477755
pii: S1472-6483(18)30526-1
doi: 10.1016/j.rbmo.2018.09.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-130

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Ernesto Bosch (E)

Instituto Valenciano de Infertilidad, Valencia, Spain. Electronic address: Ernesto.Bosch@ivi.es.

Carlo Bulletti (C)

Extra Omnes Medicina e Salute Riproduttiva, Cattolica, Italy.

Alan B Copperman (AB)

Icahn School of Medicine at Mount Sinai and Reproductive Medicine Associates of New York, New York NY, USA; Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York NY, USA.

Renato Fanchin (R)

Centre of Reproductive Medicine, Hôpital Foch, University Paris-Ouest, Suresnes, France.

Hakan Yarali (H)

Department of Obstetrics and Gynecology, Hacettepe University School of Medicine, Ankara, Turkey; Anatolia IVF and Women's Health Centre, Ankara, Turkey.

Carlos A Petta (CA)

Departamento de Ginecologia, Clinica Fertilidade e Vida, Campinas and Hospital Sirio Libanês, Sao Paulo, Brazil.

Nikolaos P Polyzos (NP)

Department of Reproductive Medicine, Dexeus University Hospital, Barcelona Spain; Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; Faculty of Health, Aarhus University, Aarhus, Denmark.

Daniel Shapiro (D)

Reproductive Biology Associates, Atlanta GA, USA.

Filippo Maria Ubaldi (FM)

G.EN.E.R.A. Centres for Reproductive Medicine Rome, Italy.

Juan A Garcia Velasco (JA)

IVI Madrid, Rey Juan Carlos University, IdIPAZ, Madrid, Spain.

Salvatore Longobardi (S)

Merck KGaA, Darmstadt, Germany.

Thomas D'Hooghe (T)

Department of Development and Regeneration, University of Leuven (KU Leuven), Leuven, Belgium; The Fertility Clinic, Skive Regional Hospital, and Faculty of Health, Aarhus University, Aarhus, Denmark.

Peter Humaidan (P)

Faculty of Health, Aarhus University, Aarhus, Denmark; The Fertility Clinic, Skive Regional Hospital, and Faculty of Health, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH